Introduction of the Horizon 2020 programme

The Horizon 2020 framework programme, which is the most impactful programme of the European Union's research and innovation policy in the 2014-2020 period, disposes a budget of near 79 billion euros. The programme is one of the corner-stones of the Innovative Union initiative named in the Europe 2020 strategy for enhancing the global competitiveness of the continent.

The Horizon 2020 programme provides direct funding, from the Bruxelles headquartered Commision, for which applications can be submitted with excellence in international competition. That means each member state can utilize as many of this funding as their capable for: the selection of the applications are based upon excellence, high quality professional management and consortia and validatable and measurable impact on all-european level.

  • the main objective of the programme is to turn innovative scientific breakthroughs into innovative products and services that provide business opportunities, and therefore provides support for all stages of the innovation chain, from research to market exploitation;
  • emphasis is placed on addressing societal challenges and solving problems affecting the society of the European Union (eg. in the fields of health, energy, transport);
  • the main types of calls are the RIA (Research and Innovation), IA (Innovation Action) and CSA (Coordination and Support action)

 

NEURAM - Visual genetics: establishment of a new discipline to visualize neuronal nuclear functions in real-time in intact nervous system by 4D Raman spectroscopy

Visual genetics: establishment of a new discipline to visualize neuronal nuclear functions in real-time in intact nervous system by 4D Raman spectroscopy

Working as a multi-disciplinary collaboration, this H2020 project aims to combine the knowledge of leading researchers and pioneering industry specialists to hone the technology and expertise needed to develop ground-breaking ways of visualising living tissue. The genetic content of a cell determines its function. Genes are constantly switched on and off from the birth of the cell up until it dies. This highly dynamic process is regulated both by internal (genetic) and external (environmental) factors. In this H2020 funded project we develop a new technology to visualise the active genes in real time.

Palliative Sedation - The use of proportional palliative sedation for the relief of refractory symptoms: an international multicenter study

The use of proportional palliative sedation for the relief of refractory symptoms: an international multicenter study — ‘PalliativeSedation’

Due to the rise in cancer and multiple chronic disease, the number of patients with refractory symptoms, ie severe symptoms where conventional treatment options fail, is likely to increase. In such cases palliative sedation (PS) can be indicated which involves the intentional lowering of consciousness at the end of life. However PS is too often restricted to continuous deep sedation and confused with hastening of death. This proposal offers a modified concept, namely proportional PS, with titration of sedatives up to the point of symptom control to improve patient comfort. Firstly, the project will offer a review about state-of-the-art refractory symptom management and a country survey. Secondly, an observational multicenter study will be performed in five countries to study the effect of proportional PS at patient comfort and symptom relief. Thirdly, a multiple case study of 50 cases will investigate caregivers and family experiences. Fourthly, moral case deliberation will be studied as a tool to improve multidisciplinary decision making for the treatment of refractory symptoms/PS in 16 clinical centers in 8 countries, including the effect on caregiver emotional distress. Fifthly, a Cost Consequence Analysis will be provided to feed a policy workshop and recommendations for the further development of palliative sedation in Europe. Sixthly, a revision of the 2009 EAPC framework for PS will be undertaken, using a Delphi procedure. Finally, a free online education programme will be delivered together with an abook and a closing congress and webinar to support dissemination. The project consortium consists of experts in the field of palliative care and PS from 8 North-Western, Southern, and Central-Eastern European countries. Renowned advisory board members are involved among which the European Cancer Patient Coalition to foster the patient perspective. A dedicated European taksforce for PS is foreseen as a follow up after the project's finalization.